Cargando…

Care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery?

PURPOSE: To describe care trajectories in patients with prolactinoma, aiming to clarify the rationale for surgery. METHODS: Retrospective observational cohort study of consecutive patients with prolactinoma undergoing surgery from 2017 to 2019 at the referral center (RC), prior to surgery being cons...

Descripción completa

Detalles Bibliográficos
Autores principales: van Trigt, Victoria R., Zandbergen, Ingrid M., Pelsma, Iris C. M., Bakker, Leontine E. H., Verstegen, Marco J. T., van Furth, Wouter R., Biermasz, Nienke R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539430/
https://www.ncbi.nlm.nih.gov/pubmed/37690076
http://dx.doi.org/10.1007/s11102-023-01346-z
_version_ 1785113499847884800
author van Trigt, Victoria R.
Zandbergen, Ingrid M.
Pelsma, Iris C. M.
Bakker, Leontine E. H.
Verstegen, Marco J. T.
van Furth, Wouter R.
Biermasz, Nienke R.
author_facet van Trigt, Victoria R.
Zandbergen, Ingrid M.
Pelsma, Iris C. M.
Bakker, Leontine E. H.
Verstegen, Marco J. T.
van Furth, Wouter R.
Biermasz, Nienke R.
author_sort van Trigt, Victoria R.
collection PubMed
description PURPOSE: To describe care trajectories in patients with prolactinoma, aiming to clarify the rationale for surgery. METHODS: Retrospective observational cohort study of consecutive patients with prolactinoma undergoing surgery from 2017 to 2019 at the referral center (RC), prior to surgery being considered a viable treatment option (i.e. PRolaCT study). Demographics and clinical data (type and duration of pretreatment and surgical indications, goals, and outcomes) were collected from patient records. Care trajectories were divided into three phases: (1) diagnosis and initial treatment, (2) endocrine treatment at the RC, and (3) surgical treatment. RESULTS: 40 patients were included (31 females (77.5%), median age 26.5 (14–63) years. Indications for surgery were dopamine agonist (DA) intolerance (n = 31, 77.5%), resistance (n = 6, 15.0%), and patient/physician preference (n = 3, 7.5%). Patients were pretreated with DA (n = 39 (97.5%)), and surgery (n = 3 (7.5%)). Median disease duration at surgery was 4 (0–27) years. Primary surgical goal was total resection in 38 patients (95.0%), of which biochemical remission was achieved 6 months postoperatively in 23 patients (62.2%), and clinical remission in 6 patients (16.2%), missing data n = 1. CONCLUSION: Care trajectories were highly individualized based on patient and tumor characteristics, as well as the multidisciplinary team’s assessment (need for alternative treatment, surgical chances and risks). Most patients were pretreated pharmacologically and had broad variation in timing of referral, undergoing surgery as last-resort treatment predominantly due to DA intolerance. High quality imaging and multidisciplinary consultations with experienced neurosurgeons and endocrinologists enabling treatment tailored to patients’ needs were prerequisites for adequate counseling in treatment of patients with prolactinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11102-023-01346-z.
format Online
Article
Text
id pubmed-10539430
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-105394302023-09-30 Care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery? van Trigt, Victoria R. Zandbergen, Ingrid M. Pelsma, Iris C. M. Bakker, Leontine E. H. Verstegen, Marco J. T. van Furth, Wouter R. Biermasz, Nienke R. Pituitary Article PURPOSE: To describe care trajectories in patients with prolactinoma, aiming to clarify the rationale for surgery. METHODS: Retrospective observational cohort study of consecutive patients with prolactinoma undergoing surgery from 2017 to 2019 at the referral center (RC), prior to surgery being considered a viable treatment option (i.e. PRolaCT study). Demographics and clinical data (type and duration of pretreatment and surgical indications, goals, and outcomes) were collected from patient records. Care trajectories were divided into three phases: (1) diagnosis and initial treatment, (2) endocrine treatment at the RC, and (3) surgical treatment. RESULTS: 40 patients were included (31 females (77.5%), median age 26.5 (14–63) years. Indications for surgery were dopamine agonist (DA) intolerance (n = 31, 77.5%), resistance (n = 6, 15.0%), and patient/physician preference (n = 3, 7.5%). Patients were pretreated with DA (n = 39 (97.5%)), and surgery (n = 3 (7.5%)). Median disease duration at surgery was 4 (0–27) years. Primary surgical goal was total resection in 38 patients (95.0%), of which biochemical remission was achieved 6 months postoperatively in 23 patients (62.2%), and clinical remission in 6 patients (16.2%), missing data n = 1. CONCLUSION: Care trajectories were highly individualized based on patient and tumor characteristics, as well as the multidisciplinary team’s assessment (need for alternative treatment, surgical chances and risks). Most patients were pretreated pharmacologically and had broad variation in timing of referral, undergoing surgery as last-resort treatment predominantly due to DA intolerance. High quality imaging and multidisciplinary consultations with experienced neurosurgeons and endocrinologists enabling treatment tailored to patients’ needs were prerequisites for adequate counseling in treatment of patients with prolactinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11102-023-01346-z. Springer US 2023-09-10 2023 /pmc/articles/PMC10539430/ /pubmed/37690076 http://dx.doi.org/10.1007/s11102-023-01346-z Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
van Trigt, Victoria R.
Zandbergen, Ingrid M.
Pelsma, Iris C. M.
Bakker, Leontine E. H.
Verstegen, Marco J. T.
van Furth, Wouter R.
Biermasz, Nienke R.
Care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery?
title Care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery?
title_full Care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery?
title_fullStr Care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery?
title_full_unstemmed Care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery?
title_short Care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery?
title_sort care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539430/
https://www.ncbi.nlm.nih.gov/pubmed/37690076
http://dx.doi.org/10.1007/s11102-023-01346-z
work_keys_str_mv AT vantrigtvictoriar caretrajectoriesofsurgicallytreatedpatientswithaprolactinomawhydidtheyoptforsurgery
AT zandbergeningridm caretrajectoriesofsurgicallytreatedpatientswithaprolactinomawhydidtheyoptforsurgery
AT pelsmairiscm caretrajectoriesofsurgicallytreatedpatientswithaprolactinomawhydidtheyoptforsurgery
AT bakkerleontineeh caretrajectoriesofsurgicallytreatedpatientswithaprolactinomawhydidtheyoptforsurgery
AT verstegenmarcojt caretrajectoriesofsurgicallytreatedpatientswithaprolactinomawhydidtheyoptforsurgery
AT vanfurthwouterr caretrajectoriesofsurgicallytreatedpatientswithaprolactinomawhydidtheyoptforsurgery
AT biermasznienker caretrajectoriesofsurgicallytreatedpatientswithaprolactinomawhydidtheyoptforsurgery